Medicare Prescription Drug Coverage of Medications for IgAN (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0655; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Medications evaluated included: SGLT2 inhibitors (dapagliflozin, Invokana (canagliflozin), Jardiance (empagliflozin), and Steglatro (ertugliflozin)), Fabhalta (iptacopan), Tarpeyo (budesonide), Vanrafia (atrasentan), Voyxact (sibeprenlimab-szsi), and Filspari (sparsentan). Interventions to improve medication access are warranted. MA-PD Plan Coverage"
Medicare • Reimbursement • US reimbursement • Chronic Kidney Disease • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease
|
|
Katie E. Cardone; Kelly Beers; Swati Mehta; Darren W. Grabe
|